JPRN-UMIN000003696招募中1 期
Phase II study of Glypican-3(GPC3) peptide vaccine as treatment for clear cell adenocarcinoma of ovary. - A Phase II study of GPC3 peptide vaccine as treatment in the clear cell adenocarcinoma of ovary
Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East0 个研究点目标入组 140 人开始时间: 2010年6月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1 Uncontrolled pleural effusion or ascites 2 There are other malignancies. 3 Active infection excluding HBV,HCV 4 Positive for HIV 5clinically significant heart disease angina within the past six months, or uncontrolled Diabetes Mellitus 6There is severe psychiatric disorder 7Pregnant or lactaing woman,who are willing to be pregnant 8Past history of severe drug allergy 9Immunodeficiency, previous splenectomy,irradiation to the spleen 10Ongoing treatment with corticosteroid or immnosuppresant drug 11Previous allogrant transplantation 12 Responsible doctors juged the patient in appropriate for the trial
研究者
相似试验
已完成
1 期
A Phase I study of Glypican-3(GPC3) Peptide Vaccine for Pediatric Patients with Refractory TumorsRefractory pediatric tumorsJPRN-UMIN000006357Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East15
已完成
2 期
A Phase II study of Glypican-3(GPC3) peptide vaccine as adjuvant treatment for Hepatocellular carcinoma(HCC) after Surgical resection or Radiofrequency ablation(RFA)JPRN-UMIN000002614Division of Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East40
已完成
1 期
Phase I clinical study of Glypican-3 peptide vaccine in patients with advanced Hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000001395Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East33
已完成
1 期
PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancerAdvanced or recurrent gastric cancer refractory to standard therapeutic modalityJPRN-UMIN000004389Department of Gastroenterological Surgery,Graduate School of Medicine,Osaka University30
已完成
2 期
Phase II study of Vaccination with Epitope peptides in combiNation with gemcitabine for UnreSectable Pancreatic Cancernresectable Pancreatic CancerJPRN-UMIN000008082Yamaguchi University Hospital60